Clinical-Grade Facial Biomarker Screening Platform.
Providing a Clinical Routing Intelligence. Resolving a $17.6B Annual Perioperative Risk.
Learn more
Entry Wedge
OSA pre-surgery $17.6B blind spot
Each year, eight million undiagnosed OSA (Obstructive Sleep Apnea) patients undergo various surgeries, many of whom experience preventable complications.
Technology
Real-time Contactless Facial Biomarkers Scanning
Regulation
Screening - Targeting FDA Class II
Validation
A clinical POC of 100 patients at HYMC. Interim results of 90% accuracy.
Go to Market
ASC chains and Hospitals first, licensing and per-use model.
IP
Pending patent securing a deep competitive moat.
Value-based Business Model
Software as a Medical Device.
The Need
Millions Are Exposed to Unnecessary Risk – Undergoing General Anesthesia Under the Wrong Protocol
of moderate and severe
OSA patients are undiagnosed
80 million Americans affected
OSA Blind Spot: Failing to screen for OSA before surgery
$17.6B USA Annual Pain
Complications and length-of-stay (LOS) after any surgery on an undiagnosed OSA patient cost hospitals and ASCs $2,200 per case.
Current Solutions Are Insufficient
Standard questionnaires have poor specificity. Sleep studies (PSG) require months of waiting — not viable for pre-surgery.
Additional Legal Risk
A single malpractice settlement arising from undetected OSA complications risks hospitals and ASCs $1.5–$4 million in damages.
Our Solution
One Scan. Zero Hardware. Real-Time Results.
Contactless rapid scan
Identifies OSA facial biomarkers
Software as a Medical Device. Unlimited scalability.
Moderate-to-severe OSA risk indication
Full workflow integration
Real-time Clinical Decision Support (CDS)
Leadership
Meet the Team
Entrepreneur
Shai Gilboa
CEO, Co-Founder
5 start-ups, 2 exits
Innovator
Itzik Wilf, Ph.D.
CTO, Co-Founder
32 years computer vision & ML
Finance
Teddy Cohen
CFO
CPA, 25 years finance & business mgmt
VP BD
Eran Cohen
VP Business Development
20+ years global strategic partnerships
Product
David Even-Haim
CPO
Vast experience in product value creation
HMO Expert
Zipi Sadeh
HMO Expert
Former Exec at Clalit, VP Community Division
Scientific Advisory Board
Chief Scientist
Prof. Yehuda G. Assaraf
Former Dean, Technion. Renowned authority in biomedical research & therapeutics.
OSA Expert · Medical Advisor
Prof. Itzhak Braverman, MD
Director, Otolaryngology & Head Neck Surgery, Hillel Yaffe Medical Centre.
CVA Expert · Medical Advisor
Prof. Eitan Uriel, MD
Director, Dept. of Neurology, Rabin Medical Center; Israeli Neurological Assoc.
Vision
One Scan, Multiple Disease Indications
OSA is only our entry point.
Future Models
Multiple-disease risk reduction platform.
Unlimited Scalability
Software only, additional disease indicators will be added via a software update.
Additional Future Use
Remote healthcare, Home Hospitalization, and Home Care monitoring and screening, B2C anywhere and anytime.
Business Potential
The technology will allow increasing Average Contract Value (ACV) with existing customers and justifying a future Per Member Per Year (PMPY) business model.
GezunTech Is The Clinical Routing Intelligence, Which Integrates Into The Existing Pre-surgical Workflow
Contact Us
eran@gezuntech.co +972-52-251-5970